Mesoblast reports financial results and operational update for fiscal year ended june 30, 2023

New york, aug. 30, 2023 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended june 30, 2023, and provided an overview of upcoming milestones.
MESO Ratings Summary
MESO Quant Ranking